Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 110, Issue 8, 2003, Pages 911-922

  Blandini, F ^a   Nappi, G ^a,b   Fancellu, R ^a,c   Mangiagalli, A ^a   Samuele, A ^a   Riboldazzi, G ^c   Calandrella, D ^c   Pacchetti, C ^a   Bono, G ^c   Martignoni, E ^a,d  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

3 O methyldopa; Catechol O methyltransferase; Dopamine; Extracellular; Intracellular

Indexed keywords

3 O METHYLDOPA; CATECHOL METHYLTRANSFERASE; DOPAMINE; ENTACAPONE; LEVODOPA; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOPAMINE METABOLISM; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE;

AGE FACTORS; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; BLOOD PLATELETS; CATECHOLS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; TYROSINE; UP-REGULATION;

EID: 10744223966     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0004-z     Document Type: Article

References (46)

1. Axelrod J, Senoh S, Witcop B (1958) O-methylation of catecholamines in vivo. J Biol Chem 233: 697-701
2. Blandini F, Martignoni E, Pacchetti C, Desideri S, Rivellini D, Nappi G (1997) Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 700: 278-282
3. Bonifati V, Meco G (1999) New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 81: 1-36
4. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ (2002) 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43: 201-207
5. Da Prada M, Borgulya J, Napolitano A, Zurcher G (1994) Improved therapy of Parkinson's disease by tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine sparing effect. Clin Neuropharmacol 17[Suppl 3]: S26-S37
6. Dean B, Copolov DL (1989) Dopamine uptake by platelets is selective, temperature dependent and not influenced by the dopamine-D1 or dopamine-D2 receptor. Life Sci 45: 401-411
7. Dingemanse J (1997) Cathecol-O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease. Drug Dev Res 42: 1-25
8. Dingemanse J (2000) Issues important for rational COMT inhibition. Neurology 55[Suppl 4]: S24-S27
9. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zurcher G, Da Prada M, van Brummelen P (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57: 508-517
10. Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM (2001) Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 24: 295-299
11. Fahn S, Elton RL and UPDRS Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. MacMillian Healthcare Information, Florham Park, NJ, pp 153-163
12. Goetz CG (1998) Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology 50[Suppl 5]: S26-S30
13. Gomes P, Soares-da-Silva P (1999) Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38: 1371-1380
14. Guttman M, Leger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A (1992) 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31: 638-643
15. Hagan RM, Raxworhty MJ, Gulliver PA (1980) Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease. Biochem Pharmacol 29: 3123-3126
16. Hammerstad JP, Pate BD, Hewitt KA, Chan GL, Ruth TJ, Calne DB (1993) The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain. Ann Neurol 34: 603-608
17. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442
18. Jorga KM, Fotteler B (1996) Clinical pharmacology of COMT-inhibitors: differences and similarities between entacapone and tolcapone. Acta Neurol Scand 94[Suppl 167]: 8
19. Juncos JL (1992) Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin 10: 487-509
20. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59: 1233-1250
21. Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60: 137-144
22. Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T (1993) The effects of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145-156
23. Keranen T, Gordin A, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Schultz E, Seppala L, Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
24. Kieburtz K, Hubble J (2000) Benefits of COMT inhibitors in levodopa-treated parkinsonian patients. Results of clinical trials. Neurology 55[Suppl 4]: S42-S45
25. Kurth MA, Adler CH (1998) COMT inhibition: a new strategy for Parkinson's disease. Neurology 50[Suppl 5]: S3-S14
26. Lautala P, Ulmanen I, Taskinen J (2001) Molecular mechanism controlling the rate and specificity of catechol-O-methylation by human soluble catechol-O-methyltransferase. Mol Pharmacol 59: 393-402
27. Mannisto PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuvants in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317-323
28. Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51: 593-628
29. Marsden CD (1994) Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 672-681
30. Martínez-Martín P, O'Brien CF (1998) Extending levodopa action - COMT inhibition. Neurology 50[Suppl 6]: S27-S32
31. Muller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H (2000) Tolcapone increases maximum concentration of levodopa. J Neural Transm 107: 113-119
32. Napolitano A, Zurcher G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 273: 215-221
33. Nutt JG (2000) Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 55[Suppl 4]: S33-S37
34. Oechsner M, Sturenburg HJ, Buhmann C, Muller D, Kunze K (1998) Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition. Eur J Neurol 5[Suppl 3]: S169
35. Olanow CW (2000) Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 57: 263-267
36. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56[11 Suppl 5]: S1-S88
37. 3H] dopamine uptake by platelet storage granules in Parkinson's disease. Life Sci 53: 1753-1759
38. Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267-271
39. Rojo A, Fontan A, Mena MA, Herranz A, Casado S, de Yebenes JG (2001) Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. Parkinsonism Relat Disord 7: 93-96
40. Ruottinen HM, Rinne UK (1998) COMT inhibition in the treatment of Parkinson's disease. J Neurol 245[Suppl 3]: P25-P34
41. Russ H, Muller T, Woitalla D, Rahbar A, Hahn J, Kuhn W (1999) Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 360: 719-720
42. Schapira AHV, Obeso JA, Olanow CW (2000) The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 55[Suppl 4]: S65-S68
43. Teravainen H, Rinne U, Gordin A (2001) Catechol-O-methyltransferase inhibitors in Parkinson's disease. Adv Neurol 86: 311-325
44. Tuomainen P, Tornwall M, Mannisto PT (1996) Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Pharmacol Toxicol 78: 392-396
45. Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-DOPA at the blood-brain barrier. Life Sci 17: 131-136
46. Zurcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 53: 497-503